Alzheimer's Research & Therapy

Table 2 Efficacy of SV2A for the early diagnosis and differential diagnosis of AD

From: Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

	CSF SV2A						Serum SV2A
	AUC (95% CI)	p-value	Cutoff (pg/mL)	SEN (%)	SPE (%)		AUC (95% CI)	p-value	Cutoff (pg/mL)	SEN (%)	SPE (%)
Con vs. aMCI	0.788 (0.647–0.891)	< 0.0001	≤ 6726.35	100.00	51.43		0.741 (0.674–0.802)	< 0.0001	≤ 5050.24	97.80	44.12
Con vs. AD	0.935 (0.857–0.978)	< 0.0001	≤ 4526.64	84.78	94.26		0.866 (0.820–0.905)	< 0.0001	≤ 1674.02	66.46	90.20
aMCI vs. AD	0.868 (0.756–0.942)	< 0.0001	≤ 3960.97	76.09	100		0.702 (0.642–0.758)	< 0.0001	≤ 1009.39	54.88	80.22
VaD vs. AD	0.905 (0.800–0.966)	< 0.0001	≤ 4526.64	84.78	92.31		0.823 (0.764–0.872)	< 0.0001	≤ 1674.02	66.46	83.72
PDD vs. AD	0.918 (0.817–0.974)	< 0.0001	≤ 4526.64	84.78	100.00		0.848 (0.790–0.895)	< 0.0001	≤ 1581.51	64.63	93.33

Note: Diagnostic accuracy was evaluated using the receiver operating characteristic (ROC) curve analysis. The Youden index was calculated to determine the best cutoff regarding sensitivity and specificity. Abbreviations: 95% CI, 95% confidence interval; AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; AUC, area under the curve; Con, control; CSF, cerebrospinal fluid; PDD, Parkinson’s disease dementia; SEN, sensitivity; SPE, specificity; SV2A, synaptic vesicle glycoprotein 2 A; VaD, vascular dementia

Back to article page

ISSN: 1758-9193

Contact us

General enquiries: journalsubmissions@springernature.com